EP Patent

EP3208337A1 — Compositions for combined inhibition of mutant egfr and il-6 expression

Assigned to Alnylam Europe AG · Expires 2017-08-23 · 9y expired

What this patent protects

The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a mutant Epidermal Growth Factor Receptor (EGFR), and methods of using the dsRNA to inhibit expression of mutant EGFR.

USPTO Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a mutant Epidermal Growth Factor Receptor (EGFR), and methods of using the dsRNA to inhibit expression of mutant EGFR.

Drugs covered by this patent

Patent Metadata

Patent number
EP3208337A1
Jurisdiction
EP
Classification
—
Expires
2017-08-23
Drug substance claim
No
Drug product claim
No
Assignee
Alnylam Europe AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.